Haleon (HLN) Expected to Announce Earnings on Thursday

Haleon (NYSE:HLN) is expected to be releasing its H1 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of $0.2669 per share and revenue of $7.4341 billion for the quarter. Interested persons can find conference call details on the company’s upcoming H1 2026 earning overview page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:00 AM ET.

Haleon Stock Performance

Shares of Haleon stock opened at $10.27 on Wednesday. The firm has a fifty day moving average of $9.40 and a two-hundred day moving average of $9.85. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92. The stock has a market capitalization of $45.21 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 2.30 and a beta of 0.13. Haleon has a 52 week low of $8.65 and a 52 week high of $11.28.

Analysts Set New Price Targets

A number of equities research analysts recently commented on HLN shares. Wall Street Zen raised Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Zacks Research lowered Haleon from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 21st. Rothschild & Co Redburn cut Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Tuesday, June 30th. Finally, Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Institutional Trading of Haleon

Large investors have recently made changes to their positions in the company. Parkside Financial Bank & Trust raised its stake in Haleon by 101.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after buying an additional 1,433 shares during the period. Geneos Wealth Management Inc. grew its stake in Haleon by 33.0% in the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after acquiring an additional 1,203 shares during the period. Caitong International Asset Management Co. Ltd grew its stake in Haleon by 428.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock valued at $57,000 after acquiring an additional 5,124 shares during the period. Cary Street Partners Financial LLC increased its holdings in shares of Haleon by 20.1% in the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock worth $69,000 after acquiring an additional 1,113 shares in the last quarter. Finally, McMillan Office Inc. bought a new stake in shares of Haleon in the fourth quarter worth about $92,000. Institutional investors own 6.67% of the company’s stock.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.